Low-dose GnRH agonist therapy for the management of endometriosis

Journal of Obstetrics and Gynaecology Research

Volumn 25, Issue 5, 1999, Pages 295-301

  Uemura, Tsuguo ^a,e   Shirasu, Kazuhiro ^a   Katagiri, Nobuyuki ^b   Asukai, Kunio ^b   Suzuki, Takeshi ^c   Suzuki, Naoyuki ^c   Osada, Hisafumi ^d   Hiroshi, Minaguchi ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b Yokohama Minami Kyosai Hospital   (Japan)

^c Saiseikai Yokohama Nanbu Hospital   (Japan)

^d YOKOHAMA MUNICIPAL CITIZEN'S HOSPITAL   (Japan)

^e Fujisawa City Hospital   (Japan)

Author keywords

Bone loss; Endometriosis; Estrogen; GnRH agonist

Indexed keywords

BUSERELIN ACETATE; ESTROGEN; GONADORELIN AGONIST;

ADULT; ARTICLE; BLEEDING; BONE ATROPHY; BONE DENSITY; BONE MINERAL; CLINICAL ARTICLE; CLINICAL TRIAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ENDOMETRIOSIS; FEMALE; HUMAN; INTRANASAL DRUG ADMINISTRATION; LUMBAR VERTEBRA;

EID: 0032755685     PISSN: 13418076     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1447-0756.1999.tb01166.x     Document Type: Article

References (10)

1. Friedman A, Lobel S, Rein M, Barbieri R. Efficacy and safety considerations in women with uterine leiomyomas treated with gonadotropin-releasing hormone agonists: The estrogen threshold hypothesis. Am J Obstet Gynecol 1990; 163: 1114-1119
2. Barbieri R. Hormone treatment of endometriosis: The estrogen threshold hypothesis. Am J Obstet Gynecol 1992; 166: 740-745
3. Uemura T, Mohri J, Osada H, Suzuki N, Katagiri N, Minaguchi H. Effect of gonadotropin-releasing hormone agonist on the bone mineral density of patients with endometriosis. Fertil Steril 1994; 62: 246-250
4. Minaguchi H, Uemura T, Shirasu K. Clinical study on finding optimal dose of a potent LHRH agonist (Buserelin) for the treatment of endometriosis-multicenter trial in Japan. In: Rolland R, Chadha D, Willemsen W, eds. Gonadotropin Down-Regulation in Gynecological Practice. New York: Alan R. Liss, Inc. 1986; 211-225
5. Dawood M. Hormonal therapies for endometriosis: Implications for bone metabolism. Acta Obstet Gynecol Scand 1994; 73: 22-34
6. Damario M, Rock J. Pain recurrence: A quality of life issue in endometriosis. Int J Gynecol Obstet (Suppl) 1995; 50: S27-S42
7. Surrey E. Steroidal and nonsteroidal 'add-back' therapy: Extending safety and efficacy of gonadotropin-releasing hormone agonists in the gynecologic patient. Fertil Steril 1995; 64: 673-685
8. Shaw R. Evaluation of treatment with gonadotropin-releasing hormone analogues. In: Shaw R, ed. Endometriosis Current Understanding Management. 1995, Oxford: Blackwell Science Ltd. 206-234
9. Lindsay P, et al. The effect of add-back treatment with tibolone (Livial) on patients treated with the gonadotropin-releasing hormone agonist triptorelin (decapeptyl). Fertil Steril 1996; 65: 342-348
10. Hornstein M, Surrey E, Weisberg G, Casino L. Leuprolide acetate depot and hormonal add-back in endometriosis: A 12-month study. Obstet Gynecol 1998; 91: 16-24